Mitochondrial Ca 2+ uptake has key roles in cell life and death. Physiological Ca 2+ signaling regulates aerobic metabolism, whereas pathological Ca 2+ overload triggers cell death. Mitochondrial Ca 2+ uptake is mediated by the Ca 2+ uniporter complex in the inner mitochondrial membrane 1,2 , which comprises MCU, a Ca 2+ -selective ion channel, and its regulator, MICU1. Here we report mutations of MICU1 in individuals with a disease phenotype characterized by proximal myopathy, learning difficulties and a progressive extrapyramidal movement disorder. In fibroblasts from subjects with MICU1 mutations, agonist-induced mitochondrial Ca 2+ uptake at low cytosolic Ca 2+ concentrations was increased, and cytosolic Ca 2+ signals were reduced. Although resting mitochondrial membrane potential was unchanged in MICU1-deficient cells, the mitochondrial network was severely fragmented. Whereas the pathophysiology of muscular dystrophy 3 and the core myopathies 4 involves abnormal mitochondrial Ca 2+ handling, the phenotype associated with MICU1 deficiency is caused by a primary defect in mitochondrial Ca 2+ signaling, demonstrating the crucial role of mitochondrial Ca 2+ uptake in humans.
Mitochondrial Ca 2+ homeostasis has key roles in many aspects of cell physiology 5 . Cellular Ca 2+ signals that mediate secretion, contraction or excitability are invariably coupled with mitochondrial Ca 2+ uptake, which in turn modulates mitochondrial bioenergetic function [5] [6] [7] , buffers cytosolic Ca 2+ signals 6, 8 and regulates Ca 2+ -mediated pathways leading to programmed and necrotic cell death 9 . Mitochondrial membrane potential (∆Ψ m ) drives Ca 2+ transport through the mitochondrial Ca 2+ uniporter (MCU) 1 . MCU is regulated by mitochondrial calcium uptake 1 (MICU1), which confers Ca 2+ sensitivity to the pathway 2, 10 . The physiological roles of the proteins involved in regulating mitochondrial Ca 2+ transport are only partially understood [11] [12] [13] and mostly derive from silencing experiments in cell culture systems, which sometimes gave conflicting results.
We studied a cohort of subjects who presented in childhood with a distinctive clinical phenotype comprising early-onset proximal muscle weakness with a static course and moderately to grossly elevated serum creatine kinase levels accompanied by learning difficulties (Supplementary Table 1 ). Subsequently, subtle extrapyramidal motor signs appeared in 10 of 15 subjects; these signs progressed over the course of several years to a debilitating disorder of involuntary movement with variable features, including chorea, tremor, dystonic posturing and orofacial dyskinesia. Additional variable features included ataxia, microcephaly, ophthalmoplegia, ptosis, optic atrophy and axonal peripheral neuropathy, all of which suggest a possible mitochondrial disorder. However, no subjects had diabetes mellitus, deafness or cardiomyopathy, and analysis of respiratory chain enzymes was normal in the muscle biopsies of all cases tested Loss-of-function mutations in MICU1 cause a brain and muscle disorder linked to primary alterations in mitochondrial calcium signaling (Supplementary Table 2 ). In subject 4, cerebral magnetic resonance imaging (MRI) showed abnormally high signal in the globus pallidus, suggestive of mitochondrial disease (Supplementary Fig. 1 ).
Muscle biopsies were available for 6 of the 15 affected individuals. All showed myopathic features, with diffuse variation in fiber size, increased frequency of internal and central nuclei (Fig. 1a) and clusters of regenerating fibers (Fig. 1b) , without pronounced fibrosis or fatty infiltration. Necrotic fibers were rare, except in one individual (subject 8b). Fiber typing was preserved, and frequent focal areas devoid of mitochondria (minicores) were observed in both type I and type II fibers in the five biopsies taken at 6 years of age or older (Fig. 1c,d) .
The consanguineous structure of family 1 suggested autosomal recessive inheritance (Fig. 2a) . We therefore performed homozygosity analysis using Affymetrix Genome-Wide Human SNP Array 6.0. Genotype data were analyzed using Snp Viewer (see URLs) and IBDfinder software 14 . We identified a single region of concordant homozygosity shared by the affected individuals on chromosome 10 at positions 73,825,652-78,713,115 (Fig. 2b) .
Whole-exome sequencing of subject 2a (Fig. 1a) identified only one potentially pathogenic variant in the homozygous region-a splice acceptor site mutation, c.1078-1G>C in MICU1 (NM_006077.3; Fig. 2c ). This variant segregated with the phenotype in family 1 and was not seen in 22 ancestry-matched in-house exomes or in 372 ancestrymatched control alleles analyzed by PCR. Whole-exome sequencing of two further affected individuals (UK10K_NM5061923 and UK10K_ NM5061924, subjects 8a and 8b, respectively) was performed concurrently as part of the UK10K project, with variants called and filtered as previously described 15 . The homozygous c.1078-1G>C variant was also found in both of these affected individuals. This variant was absent from dbSNP137, the 1000 Genomes Project database, the National Heart, Lung and Blood Institute (NHLBI) Exome Variant Server of 6,500 exomes, the UK10K twins cohort and the ClinSeq study. Sanger sequencing (Supplementary Table 3 ) identified the same variant in six additional affected individuals from three UK-Pakistani families. In contrast, whole-exome sequencing of two unrelated Dutch families of European ancestry (subjects LUMC1 and LUMC2 or UMCU1 and UMCU2; Supplementary Figs. 2 and 3) , in which children presented with proximal myopathy, elevated serum creatine kinase levels and a movement disorder, identified a different homozygous mutation affecting a splice donor site, c.741+1G>A (Fig. 2c) . We identified a total of 15 affected individuals from 7 families. Neither the UK-Pakistani families nor the Dutch families of European ancestry were knowingly related to each other; however, genotype data for microsatellites flanking MICU1 suggested a common ancestral origin for individuals carrying each of the two variants ( Supplementary  Fig. 4 ). All variant and phenotype data were submitted to the Leiden Open Variation Database (LOVD; see URLs). Table 4 ) from subjects with each of the splice-site mutations showed intronic insertions causing frameshifts (Supplementary Figs. 5 and 6 ). Transcripts were shown by quantitative PCR (qPCR) to undergo nonsense-mediated decay (Fig. 2d) , and loss of protein was confirmed by protein blot (Supplementary Fig. 7) . Consistent with the clinical features displayed by affected individuals, Micu1 was highly expressed in normal mouse muscle and brain ( Supplementary Figs. 8 and 9) .
To evaluate the physiological consequences of the absence of MICU1 protein, we analyzed cellular and mitochondrial Ca 2+ homeostasis in primary fibroblasts from two healthy individuals and two unrelated affected individuals (subjects 6 and 8a; Supplementary Figs. 10 and 11 and Supplementary Table 1) under resting conditions and after stimulation with a Ca 2+ -mobilizing agonist (histamine; 10 µM). Mitochondrial and cytosolic Ca 2+ concentrations were measured using mitochondria-targeted aequorin 1 and Fluo-4, respectively. The initial rate of histamine-induced mitochondrial Ca 2+ uptake was increased in MICU1-deficient fibroblasts (Fig. 3a,b) , indicating increased mitochondrial Ca 2+ load at lower cytosolic Ca 2+ concentrations, whereas the peak mitochondrial Ca 2+ concentration was unchanged (Fig. 3c) . The increased velocity of Ca 2+ uptake was not due to differences in mitochondrial membrane potential (Fig. 3d) or to altered endoplasmic reticulum (ER) Ca 2+ content ( Supplementary  Fig. 12a ). The increased rate of mitochondrial Ca 2+ uptake could result from increased proximity of the mitochondrial pool to the ER, thus exposing the mitochondria to microdomains with higher calcium concentrations. We therefore explored mitochondrial proximity to the ER using immunofluorescence. These data did not show any significant change in the closeness of mitochondrial pool to the ER (Supplementary Fig. 13 ). Although we recognize that electron microscopy data might be more precise in this analysis, it is important to note that changes in ER-mitochondria contacts due to altered expression of related proteins can be observed using immunofluorescence 16, 17 . 
npg l e t t e r S
Because aequorin is not suitable for the quantification of low, submicromolar Ca 2+ concentrations 18 , to better appreciate the relationship between cytosolic and mitochondrial Ca 2+ concentrations close to basal levels, we used cells loaded with Rhod-2 for imaging with high temporal resolution; this probe has higher Ca 2+ affinity than aequorin and also allows simultaneous measurement of the Ca 2+ concentrations in both compartments 19 . Despite the limitations inherent to this assay, the resting mitochondrial Ca 2+ concentration was significantly higher in MICU1-deficient cells compared to controls, and the velocity of mitochondrial Ca 2+ uptake was significantly increased (Fig. 3e-j) . This elevated mitochondrial Ca 2+ concentration of MICU1-deficient cells at rest was confirmed by ratiometric measurements using the recombinant 2mtGCaMP6 probe (Fig. 3h) . Plotting mitochondrial versus cytosolic Ca 2+ concentrations showed that MICU1 deficiency caused loss of the physiological cooperative sigmoid regulation of mitochondrial Ca 2+ concentrations 7 (Fig. 3j) , resulting in higher basal Ca 2+ load in the organelle and a rapid response to changing cytosolic Ca 2+ concentrations. These results are in accordance with the previously described function of the MICU1 protein in other cell types 10 . In addition, the histamine-induced global peak cytosolic Ca 2+ concentration in MICU1-deficient cells was significantly reduced compared to control cells (Fig. 3k,l) . This finding is consistent with increased mitochondrial Ca 2+ buffering, as the effect was prevented through the inhibition of mitochondrial Ca 2+ uptake with the uncoupler FCCP (carbonyl cyanide 4-(trifluoromethoxy)phenylhyd razone; Fig. 3m ) and as ER Ca 2+ content was unchanged in MICU1-deficient cells (Supplementary Fig. 12a) .
Confocal imaging of mitochondria loaded with the mitochondrial membrane potential-sensitive dye TMRM (tetramethylrhodamine; Fig. 4a,b) or the Ca 2+ -sensitive probe Rhod-2 (Fig. 4c,d) showed that a substantial proportion of MICU1-deficient cells had a highly fragmented mitochondrial network. In addition, the intensity of Rhod-2 fluorescence in MICU1-deficient cells that showed a fragmented mitochondrial network was significantly greater than in cells without fragmentation, suggesting that mitochondrial fragmentation is associated with increased resting mitochondrial Ca 2+ concentrations (Fig. 4e) . Moreover, expression of wild-type MICU1 in MICU1-deficient (f,g) MICU1 was expressed in control and ∆MICU1 (8a and 6) cells using an adenoviral construct that also expressed GFP. Cells loaded with TMRM (f) and Rhod-2 (g) were imaged using a high-content imaging system (ImageXpress), and cells positive or negative for GFP were analyzed for morphology (f) or basal mitochondrial Ca 2+ concentration (g). Details of normalization of the Rhod-2 signal and of morphology scoring are described in Supplementary Figures 13 and 14 , respectively. NT, no treatment. (h,i) NAD(P)H fluorescence was imaged using UV confocal microscopy (h) and quantified (i) in resting cells and ones stimulated with histamine (10 µM). Scale bars, 20 µm (b,d) and 10 µm (h). (j) Oxygen consumption of intact control and MICU1-mutant fibroblasts was measured in suspension using high-resolution respirometry. Basal, leakage (in the presence of 2.5 µM oligomycin) and maximal (in the presence of 1 µM FCCP) respiration are shown. (k) Effect of histamine (10 µM) on basal respiration, measured 1 min after the addition of the agonist. The number of images and cells analyzed in f,g are described in the Online Methods. For pairwise comparison of means in k, t tests were used; otherwise, one-way ANOVA was used with post hoc Bonferroni tests for each sample. Bar graphs show mean ± s.e.m. from three separate experiments. *P < 0.05.
npg l e t t e r S cells rescued this phenotype (Fig. 4f,g and Supplementary Figs. 14  and 15) . Together, these data show that loss of MICU1 leads to chronic activation of the MCU channel, even at resting cytosolic Ca 2+ concentrations, and, hence, to Ca 2+ -induced fragmentation of the mitochondrial network.
As an increased mitochondrial matrix Ca 2+ concentration activates the tricarboxylic acid cycle 18 , it has also been suggested that MICU1 regulates Ca 2+ -mediated activation of mitochondrial energy metabolism through its role as the Ca 2+ sensor of the MCU complex 10 . NAD(P)H autofluorescence was significantly higher in MICU1-deficient cells, consistent with this model (Fig. 4h,i) . Measurements of NAD(P)H fluorescence after histamine stimulation showed that the maximal mitochondrial Ca 2+ concentration mediates a change in energy metabolism 20 . Metabolism was not significantly different in control and MICU1-deficient cells (Fig. 4i) , consistent with the aequorin measurements of peak histamine-stimulated mitochondrial Ca 2+ concentrations (Fig. 3a,c) . The small but significant increase in NAD(P)H levels after histamine stimulation of MICU1-deficient cells (Fig. 4i) shows that the increase in resting mitochondrial Ca 2+ concentrations in these cells is not sufficient to saturate the Ca 2+ -dependent metabolic pathway. No significant differences could be detected in either basal or histamine-induced mitochondrial oxygen consumption or in respiratory control or respiratory reserve capacity in control and MICU1-deficient fibroblasts (Fig. 4j,k) , in keeping with the unchanged mitochondrial membrane potential (Fig. 3d) .
These data show that loss of MICU1 protein results in a complex cellular phenotype due to increased mitochondrial Ca 2+ load, both at basal cytosolic Ca 2+ concentrations and after spontaneous, low-frequency, transient increases in cytoplasmic Ca 2+ levels ( Supplementary Fig. 12b-e) . The reduction in cytoplasmic Ca 2+ signals as a result of enhanced mitochondrial Ca 2+ buffering could disturb Ca 2+ -dependent processes such as muscle contraction and synaptic transmission. Furthermore, chronic activation of the MCU channel and subsequent chronic elevation of the mitochondrial matrix Ca 2+ load might lead to moderate mitochondrial stress, as reflected by the fragmented phenotype seen in a proportion of MICU1-deficient cells. However, at least under resting conditions, the fibroblasts from affected individuals seemed to compensate for stress-induced dysfunction, without apparent defects in overall cellular metabolic function. The slow progression of the clinical features in affected individuals seems to be consistent with limitations of these compensatory mechanisms in vivo in the long term.
The dysfunction in mitochondrial Ca 2+ uptake described in these individuals results in a previously unrecognized phenotype, the clinical and pathological features of which overlap with those of muscular dystrophies, congenital core myopathies and mitochondrial myopathies. Mitochondrial damage and dysfunction are features common to these disorders. In Duchenne muscular dystrophy, sarcolemmal damage leads to the dysregulation of cellular Ca 2+ homeostasis and mitochondrial Ca 2+ overload-induced necrosis of myocytes 3 . In Ullrich congenital muscular dystrophy, deficiency in collagen VI causes defects in mitochondrial architecture, Ca 2+ dysregulation and cell death 21 . In core myopathies, mutations in the type 1 ryanodine receptor gene (RYR1) lead to Ca 2+ leakage from the sarcoplasmic reticulum and consequent muscle dysfunction 4 . In these diseases, early pathological changes affect confined areas of muscle fiber. Within these areas, initial mitochondrial or sarcoplasmic reticulum disruption causes loss of local Ca 2+ sequestration, resulting in mitochondrial swelling and disruption and, eventually, complete loss of mitochondria from the cores 4 .
The increased velocity of mitochondrial Ca 2+ uptake and resting mitochondrial Ca 2+ loading that we have seen in individuals with MICU1 mutations define a primary defect in mitochondrial Ca 2+ uptake as a new mechanism underlying neuromuscular disease. The phenotype described provides much-needed in vivo insight into the biological role of this regulator of mitochondrial Ca 2+ signaling.
URLs. Snp Viewer, http://sourceforge.net/projects/snpviewer/; MICU1 homepage, http://www.LOVD.nl/MICU1; Picard tools, http:// picard.sourceforge.net/; ImageJ, http://rsbweb.nih.gov/ij/; Primer3, http://bioinfo.ut.ee/primer3-0.4.0/; JACoP v2.0 plugin, http://rsbweb. nih.gov/ij/plugins/track/jacop.html.
MetHods
Methods and any associated references are available in the online version of the paper. 
oNLINe MetHods
Research subjects. All families provided written informed consent, and this study was approved by the boards of the Leeds East and Great Ormond Street Hospital research ethics committees (references Leeds East 07/H1306/113 and GOSH 00/5802, respectively) and the institutional review board of the University of Leiden. Patients were recruited from the muscle clinics of the above institutions. We used standard methods to isolate genomic DNA from the peripheral blood of the affected children and family members or from frozen fetal tissue or amniocytes. Chromosome analysis was performed for at least one affected individual for each family.
Histology, histochemistry and immunohistochemistry. All histological and histochemical studies and staining with hematoxylin and eosin, NADH, succinate dehydrogenase (SDH) and cytochrome c oxidase (COX) were performed on frozen sections (10 µm) 22 . Immunohistochemical studies were performed at room temperature. Briefly, unfixed frozen serial sections ( Whole-exome sequencing. Alignment and variant calling. Target capture was performed using the Agilent SureSelect All Exon v4 exome enrichment kit according to standard manufacturer protocols. Sequencing of 80-bp reads was performed using an Illumina Genome Analyzer IIx. Reads were aligned to GRCh37 using Novoalign (Novocraft Technologies) and were processed using the Genome Analysis Toolkit (GATK) 23 and Picard (see URLs) to perform indel realignment and duplicate removal. Single-nucleotide variants (SNVs) and indel variants were called using the UnifiedGenotyper feature of GATK.
Filtering. Bespoke Perl scripts were used to remove variants present in dbSNP129 or with a minor allele frequency of ≥1% in dbSNP132 and to annotate functional consequences. Variants present in another 22 in-house exomes were also removed. Of the RefSeq coding bases within the autozygous region identified in family 1, 91.9% were covered by at least five good-quality reads (minimum Phred-like base quality of 17 and minimum mapping quality of 20). We selected variants that were indels within coding regions, nonsynonymous SNVs or alterations of splice consensus sequences. After the filtering described above, three such variants were identified in the autozygous region identified in family 1, comprising two missense SNVs in DUSP13 (NM_001007273; c.223A>G, p.Ser75Gly and c.746G>A, p.Cys249Tyr) and alteration of the invariant splice acceptor site in MICU1. Both missense variants were predicted to be benign by Polyphen, SIFT and Condel and had a global minor allele frequency greater than 30% in 1000 Genomes Project data, leaving the splice-site mutation in MICU1 as the only likely pathogenic variant (NM_001195518; c.1078-1G>C).
Mutation analysis. Primers were designed for all coding exons of MICU1 using Primer3 (Supplementary Table 2) 24 . Direct sequencing was performed using the dideoxy chain termination method (ABI BigDye 3.0 system) on an ABI 3730 DNA sequencer, and sequences were analyzed using 4Peaks software.
Gene expression analyses with quantitative RT-PCR. MICU1 expression in patient and control fibroblasts was analyzed by quantitative RT PCR. Total RNA was converted to cDNA using the SuperScript III First-Strand cDNA system (Life Technologies). PCR analysis of cDNA was performed using PAGE-purified primers specific for human MICU1 (Sigma-Aldrich), after optimization to eliminate primer dimers and subsequent confirmation by analysis of amplimer dissociation curves after a qPCR run. Each reaction was run in triplicate. Amplimer amounts were quantified continuously with the SYBR GreenER qPCR system (Invitrogen) using an ABI 7500 instrument, essentially as described previously 25 . 36B4 cDNA was amplified for normalization.
Cell culture. Skin biopsies were taken from affected individuals after obtaining informed consent. Control skin samples were obtained from pediatric subjects (undergoing surgical procedures) with no known neuromuscular disease after obtaining written informed research consent. Fibroblasts were grown from skin explants and cultured in DMEM (Invitrogen) supplemented with 20% FBS (Invitrogen), 1% l-glutamine (Sigma) and 1% penicillin-streptomycin and neomycin (Sigma) at 37 °C in 5% CO 2 . Cell lines established from affected individuals were confirmed to harbor the correct homozygous mutation in MICU1 by Sanger sequencing before functional studies were performed. Cell lines were routinely tested for mycoplasma contamination.
MICU1 expression and protein blotting. The adenovirus expressing MICU1-HA and GFP was created using the AdEasy strategy (Stratagene). Adenoviral vectors contain two distinct promoters that independently drive the expression of the gene of interest and GFP. Therefore, the mock plasmid expresses only GFP protein. Cells were grown in DMEM supplemented with 10% FBS and were infected with the different adenoviruses at a multiplicity of infection of 50 PFU/cell.
After 48 h, cells were lysed in RIPA lysis buffer (1% Triton X-100, 0.1% SDS, 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% sodium deoxycholate, 1 mM EDTA and Complete EDTA-free protease inhibitor mixture (Roche Applied Science)), and protein was quantified with the BCA method (Pierce). Total protein (40 µg) was separated by SDS-PAGE, transferred to Hybond-C Extra membrane (Amersham) and stained with Ponceau S solution. MICU1-HA was visualized with a polyclonal antibody to HA (Sigma), H6908. All antibodies were used at a dilution of 1:1,000 and were from Sigma (MCU, hpa016480; MICU1, hpa037480) or Santa Cruz Biotechnology (TOM20). Secondary, HRP-conjugated antibodies (1:5,000 dilution) were from Bio-Rad (170-6515 and 170-6516).
Immunofluorescence and analysis of ER-mitochondria colocalization.
Control and MICU1-mutant cells were plated on glass coverslips and were either left untreated or treated with 1 µM thapsigargin for 24 h. Cells were fixed in 4% paraformaldehyde (20 min at room temperature), washed in PBS (5 min) and blocked in PBS containing 1% BSA and 1% FBS (1 h at room temperature). Primary antibodies (grp75, sc-1058, Santa Cruz Biotechnology; PDI-A3, hpa003230, Sigma) were used at a 1:200 dilution (overnight at 4 °C). For visualization of grp-75 (mitochondria) and PDIA3 (ER), the appropriate Alexa Fluor 488-and Alexa Fluro 594-conjugated secondary antibodies were used, respectively (1 h at room temperature, 1:200 dilution; Invitrogen). Cells were imaged using a Zeiss 700 CLSM confocal system, with 488-and 535-nm lasers for excitation, emission settings for optimal separation, as calculated using Zeiss ZEN acquisition software, and a 63×, 1.4 N.A. oil objective. z series of images were acquired using a pinhole diameter of <1 Airy units (AU) and a distance between z planes of <400 nm. Settings for acquisition and thresholding were kept standard for the entire experimental set. Colocalization of red and green signals was quantified with the JACoP v2.0 plugin 26 in ImageJ (see URLs). Mander's coefficients for the two signals estimating the amount of colocalizing signal from one channel compared to the other were calculated and are shown (Supplementary Fig. 14b ). To visualize colocalizing pixels, we used the resulting Costes overlay images.
Live-cell confocal imaging of mitochondrial membrane potential and NAD(P)H. Confocal imaging was used to measure mitochondrial membrane potential, mitochondrial resting Ca 2+ content and NAD(P)H redox state and to assay mitochondrial morphology. For all imaging experiments, cells were grown on 22-mm glass coverslips or 35-mm imaging dishes (WPI). Measurements were carried out in recording buffer (138 mM NaCl, 5.6 mM KCl, 4.2 mM NaHCO 3 , 1.2 mM NaH 2 PO 4 , 1.2 mM MgCl 2 , 2.6 mM CaCl 2 , 10 mM d-glucose and 10 mM HEPES). All images were acquired on a Zeiss 700 CLSM or a Zeiss 510 UV-VIS CLSM. For measurements of mitochondrial
